TriSalus Life Sciences, Inc. TLSI

TLSI Company Overview

TriSalus Life Sciences, Inc. is a U.S.-based oncology company focused on developing and commercializing technologies and therapeutics intended to improve the delivery and effectiveness of treatments for liver and pancreatic cancers. The company operates at the intersection of interventional oncology and immunotherapy, combining proprietary drug-delivery systems with investigational biologic therapies. TriSalus primarily serves hospitals, interventional radiologists, oncologists, and cancer treatment centers involved in minimally invasive cancer care. Its operations are centered on improving treatment access to difficult-to-treat solid tumors through pressure-enabled drug delivery and immune-modulating therapies.

The company’s primary commercial platform is the TriNav® Infusion System, a pressure-enabled drug delivery technology designed to optimize the administration of embolic agents and therapeutics directly into tumors while reducing reflux during procedures. In parallel, TriSalus is developing nelitolimod, an investigational Toll-like receptor 9 (TLR9) agonist being evaluated in combination with checkpoint inhibitors and other therapies for pancreatic and liver cancers. TriSalus evolved from technology and therapeutic development efforts in interventional oncology and became publicly traded through a business combination transaction completed in 2023. The company positions itself as an integrated oncology platform combining device-enabled drug delivery with immunotherapy development.